
Insmed (INSM) Stock Forecast & Price Target
Insmed (INSM) Analyst Ratings
Bulls say
Insmed is a biopharmaceutical company with a positive outlook, driven by the strong commercial performance of its two respiratory products, Arikayce and Brinsupri. The company has a diverse and promising pipeline focused on respiratory, immunology, and rare neurological diseases, supported by various technologies and modalities. With its strong financial position and expectations for significant revenue growth from its lead programs, Insmed is a top pick for investors.
Bears say
Insmed is facing significant downside risks to its price target and rating due to clinical and commercial risks associated with its products, including Arikayce and TPIP. Additionally, strong competition from other companies in the same therapeutic areas may hinder Insmed's commercial success, especially for its TPIP product which faces competition from Tyvaso and Yutrepia. Changes to Insmed's financial model, including increased expenses and delays in product launches, also contribute to our negative outlook on the stock.
This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.
Insmed (INSM) Analyst Forecast & Price Prediction
Start investing in Insmed (INSM)
Order type
Buy in
Order amount
Est. shares
0 shares